At Alex Therapeutics, we develop CE-certified Digital Therapeutics (DTx) products.
We are a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artifical Intelligence to provide our patients with highly personalized and effective care.
Our first product, Alex AI - Quit Smoking, combines CBT with AI to help patients treat Nicotine Addiction. So far over 100,000 patients have chosen Alex AI to help them overcome their Nicotine Addiction.
The Alex Platform allows for the easy development of new products and we see incredible potential in future verticals such as obesity, depression, oncology and more.
We’re always looking for great new partners and co-workers. Send us an email at hello@alextherapeutics.com to get in touch.
We are a pioneer within our field, combining Cognitive Behavioural Therapy (CBT) and Acceptance and Commitment Therapy (ACT) with Artifical Intelligence to provide our patients with highly personalized and effective care.
Our first product, Alex AI - Quit Smoking, combines CBT with AI to help patients treat Nicotine Addiction. So far over 100,000 patients have chosen Alex AI to help them overcome their Nicotine Addiction.
The Alex Platform allows for the easy development of new products and we see incredible potential in future verticals such as obesity, depression, oncology and more.
We’re always looking for great new partners and co-workers. Send us an email at hello@alextherapeutics.com to get in touch.
Location: Sweden, Stockholm
Employees: 11-50
Total raised: $3.82M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 19.04.2022 | Hadean Ven... | hadeanvent... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.04.2022 | - | $3.82M | - |
Mentions in press and media 20
| Date | Title | Description |
| 15.09.2024 | A Digital Lifeline: Alex Therapeutics and Navamedic Unite for Parkinson’s Care | In a world where technology meets healthcare, a new partnership is emerging. Alex Therapeutics and Navamedic have joined forces to develop a Companion App aimed at transforming the treatment landscape for Parkinson’s disease. This collabora... |
| 12.09.2024 | Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease | Navamedic announces an exclusive agreement with Alex Therapeutics for the development of a Companion App to aid in the treatment of Parkinson’s Disease Thu, Sep 12, 2024 12:00 CET Report this content Stockholm Sweden, September 12, 2024 - N... |
| 12.09.2024 | Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease | Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion App to aid in the treatment of Parkinson’s Disease Thu, Sep 12, 2024 12:00 CET Report this content Stockholm Sweden, September 12, 2024 - ... |
| 04.01.2024 | Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial | Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investigating the efficacy of Almee, a 9-week digital CBT intervention accessed through a smartphone or tablet. The study met its primary endpoint,... |
| 04.01.2024 | Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety | Alex Therapeutics Reports Positive Results from the Randomized-Controlled Trial of its Digital Therapy for Anxiety Thu, Jan 04, 2024 08:30 CET Report this content ● AlmeeTM, developed by Alex Therapeutics in partnership with Vicore Pharma, ... |
| 21.12.2023 | Hadean Ventures announces oversubscribed final close of Hadean Capital II | Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital I... |
| 05.03.2023 | Alex Therapeutics extends financing round to €4.75M with leading life science VC | Innovestor Life Science, a leading biotech and digital health VC, invests €1.25M in the digital therapeutics (DTx) company Alex Therapeutics. With this extension, the company has secured a total of €4.75M this round. Innovestor joins an imp... |
| 13.10.2022 | Alex Therapeutics presents results from digital therapeutic pilot study showing nearly 50% reduction in anxiety | The Digital Therapeutic (DTx) was developed by DTx leader Alex Therapeutics using the proprietary "Alex DTx Platform"[1] in partnership with Vicore Pharma In the study patients with Idiopathic Pulmonary Fibrosis (IPF) and anxiety ... |
| 21.04.2022 | Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF) | Vicore launches COMPANION, a clinical study investigating the benefit of digital therapy on anxiety in patients with idiopathic pulmonary fibrosis (IPF) Thu, Apr 21, 2022 09:30 CET Report this content First clinical study with a digital the... |
| 21.04.2022 | Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with idiopathic pulmonary fibrosis (IPF) has launched in the US | Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with idiopathic pulmonary fibrosis (IPF) has launched in the US Thu, Apr 21, 2022 16:01 CET Report this content The D... |
Show more